KRYS Nasdaq Biotechnology Financials FY2016βFY2025
Krystal Biotech had $389M of revenue in fiscal 2025, up 33.9% on the year before.
Hi! I read Krystal Biotechβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+33.9%
Yes. Sales grew 33.9% last year.
Does it make a profit?
52.6%
Yes. It keeps 52.6% of every sale as profit.
Does profit turn into cash?
48.6%
Yes. 48.6% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
39.0x
One share costs 39.0 times its yearly profit per share. Typical for its sector: 27.9x.
Rules of thumb on reported numbers. A starting point, not a recommendation.
About these figures. Krystal Biotech has had no borrowings since its 2017 listing (its balance sheets have no debt line), so debt is zero from 2017.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Krystal Biotech did it, and the next one. Share prices often move a lot on those days.
Next results
November 2, 2026
Monday Β· in 7 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 3, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 4, 2026 | Q1 '26 | Before the market opens | 10-Q β |
| Jan 11, 2026 | Q4 '25 | Time not announced | 8-K β |
| Nov 3, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Aug 4, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 6, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Feb 19, 2025 | Q4 '24 | Before the market opens | 10-K β |
| Nov 4, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Krystal Biotech had $389M of revenue in fiscal 2025, up 33.9% on the year before. Its operating margin was 41.5%, up 18.8Β pts: of every 100 in sales, about 41 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Krystal Biotech made $205M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $189M in fiscal 2025, 48.6% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Krystal Biotech returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 0.7%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $60.9M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$60.9M
6 insiders
Of sales under plans
86%
$52.7M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Krish S KrishnanPresident and CEO, Director, 10% owner | Sold plan | 25,000 | $359.32 | $9.0M | Form 4 |
| Sep 4, 2026 | Suma KrishnanPresident, R&D, Director, 10% owner | Sold plan | 25,000 | $359.32 | $9.0M | Form 4 |
| Aug 14, 2026 | Dino A RossiDirector | Sold | 25,000 | $329.12 | $8.2M | Form 4 |
| Jun 25, 2026 | John Charles ThomasEVP, General Counsel | Sold plan | 1,000 | $347.27 | $0.3M | Form 4 |
| Jun 4, 2026 | Krish S KrishnanPresident and CEO, Director, 10% owner | Sold plan | 25,000 | $308.12 | $7.7M | Form 4 |
| Jun 4, 2026 | Suma KrishnanPresident, R&D, Director, 10% owner | Sold plan | 25,000 | $308.12 | $7.7M | Form 4 |
| May 26, 2026 | John Charles ThomasEVP, General Counsel | Sold plan | 642 | $302.03 | $0.2M | Form 4 |
| Mar 4, 2026 | Krish S KrishnanPresident and CEO, Director, 10% owner | Sold plan | 25,000 | $263.17 | $6.6M | Form 4 |
| Mar 4, 2026 | Suma KrishnanPresident, R&D, Director, 10% owner | Sold plan | 25,000 | $263.21 | $6.6M | Form 4 |
| Mar 2, 2026 | Kathryn RomanoChief Accounting Officer | Sold plan | 750 | $267.60 | $0.2M | Form 4 |
| Feb 27, 2026 | Daniel JanneyDirector | Sold plan | 11,803 | $275.59 | $3.3M | Form 4 |
| Feb 26, 2026 | Daniel JanneyDirector | Sold plan | 7,741 | $275.63 | $2.1M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· Krystal Biotech has $828M more cash than debt.
Cash, debt and the ratios that show how comfortably Krystal Biotech can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $438M | $379M | $532M | $598M | $828M |
| Debt incl. finance leases | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net debt / EBITDA | β | β | β | β8.3x | β5.0x |
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | β45.8x | β | β | β | β |
| Current ratio | 17.2x | 13.3x | 17.8x | 7.3x | 10.0x |
| Quick ratio | 17.2x | 13.3x | 17.6x | 7.0x | 9.6x |
| Total assets | $626M | $558M | $818M | $1.1B | $1.3B |
| Total liabilities | $32.7M | $36.2M | $39.7M | $110M | $114M |
| Shareholders' equity | $594M | $522M | $779M | $946M | $1.2B |
| Net debt (β = net cash) | β$438M | β$379M | β$532M | β$598M | β$828M |
KIRA Β· Its return on capital was 43.6%: every 100 invested in the business earned about 44 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Krystal Biotech passes 5 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | 4 / 8 | 5 / 8 | 5 / 8 |
| Accruals ratio | 14.5% | β3.7% | 0.3% |
| Altman Z'' | 23.06 | 12.92 | 16.61 |
What does the share cost, and how does it compare?
KIRA Β· At $311.50 a share, the company is worth $9.6B: 39.0 times its earnings of the last four quarters.
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets β the answer depends entirely on what you put in.
In plain words: Move the sliders to try your own guesses about growth. The result is what one share would be worth if those guesses came true. Different guesses give very different answers.
Value per share
β
Adds net cash of $828M and divides by 30.0M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Value per share
β
Reference multiples: today 39.0x Β· peers 23.8x Β· sector 27.9x.
KIRA Β· Krystal Biotech grew sales faster than 2 of its 4 similar companies. Its P/E is higher than 2 of 2.
Each companyβs latest fiscal year. Fiscal years end in different months, so periods donβt line up exactly.
In plain words: The same numbers for similar companies, so you can tell whether a figure is high or low for this kind of business.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Krystal Biotech KRYS | $9.6B | 33.9% | 41.5% | 48.6% | 43.6% | 39.0x | 5 | |
| ADMA Biologics ADMA | $2.5B | 19.6% | 37.5% | 5.5% | 39.5% | 15.3x | 5 | Compare β |
| Ligand Pharmaceuticals LGND | $6.6B | 60.4% | 15.3% | 18.2% | 4.9% | 32.3x | 5 | Compare β |
| Repligen RGEN | β | 16.4% | 7.5% | 12.7% | 2.4% | β | β | Compare β |
| Arrowhead Pharmaceuticals ARWR | $8.3B | 23,258.2% | 11.9% | 18.9% | β | β | 5 | Compare β |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | β | β | β | β | β | $0.0M | $0.0M | $50.7M | $291M | $389M |
| Research and development | $0.7M | $3.2M | $7.8M | $15.6M | $17.9M | $27.9M | $42.5M | $46.4M | $53.6M | $58.0M |
| Operating income | β$1.1M | β$4.8M | β$11.9M | β$22.1M | β$33.0M | β$68.3M | β$145M | β$110M | $65.7M | $161M |
| Interest expense | β | β | β | β | $0.0M | $1.5M | $0.0M | $0.0M | β | β |
| Pretax income | β | β$7.9M | β$10.9M | β$19.1M | β$32.2M | β$69.6M | β$140M | $12.9M | $95.4M | $190M |
| Income tax | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $2.0M | $6.2M | β$15.4M |
| Net income | β$1.1M | β$7.9M | β$10.9M | β$19.1M | β$32.2M | β$69.6M | β$140M | $10.9M | $89.2M | $205M |
| Diluted EPS | β$1.31 | β$1.48 | β$0.97 | β$1.20 | β$1.71 | β$3.13 | β$5.49 | $0.39 | $3.00 | $6.84 |
| Diluted shares | 0.00B | 0.01B | 0.01B | 0.02B | 0.02B | 0.02B | 0.03B | 0.03B | 0.03B | 0.03B |
| Cash flow | ||||||||||
| Cash from operations | β$1.3M | β$3.9M | β$9.4M | β$18.7M | β$26.1M | β$47.9M | β$101M | β$88.8M | $123M | $201M |
| Capital expenditure | $0.0M | $0.2M | $2.2M | $6.4M | $14.8M | $68.3M | $53.0M | $11.8M | $4.2M | $12.0M |
| Free cash flow | β$1.3M | β$4.1M | β$11.7M | β$25.1M | β$40.9M | β$116M | β$154M | β$101M | $119M | $189M |
| Depreciation and amortization | $0.0M | $0.0M | $0.1M | $1.1M | $1.9M | $2.8M | $4.1M | $5.0M | $6.0M | $5.7M |
| Stock-based compensation | $0.0M | $0.2M | $0.8M | $1.2M | $3.3M | $15.3M | $33.2M | $39.9M | $49.1M | $54.5M |
| Acquisitions | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $1.9M | $49.6M | $112M | $194M | $271M | $438M | $379M | $532M | $598M | $828M |
| Total debt | $1.1M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Current assets | $2.2M | $49.9M | $113M | $196M | $275M | $442M | $384M | $588M | $742M | $1.0B |
| Current liabilities | $0.0M | $0.6M | $2.6M | $3.3M | $15.5M | $25.7M | $28.8M | $33.1M | $102M | $103M |
| Inventory | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $7.0M | $26.5M | $40.5M |
| Property and equipment, net | $0.0M | $0.2M | $3.0M | $8.5M | $30.9M | $112M | $162M | $161M | $155M | $151M |
| Total assets | $2.2M | $50.1M | $116M | $209M | $311M | $626M | $558M | $818M | $1.1B | $1.3B |
| Total liabilities | $1.9M | $0.6M | $2.9M | $6.1M | $18.8M | $32.7M | $36.2M | $39.7M | $110M | $114M |
| Shareholders' equity | $0.3M | $49.5M | $113M | $203M | $292M | $594M | $522M | $779M | $946M | $1.2B |
| Margins | ||||||||||
| Operating margin | β | β | β | β | β | β | β | β216.2% | 22.6% | 41.5% |
| EBITDA margin | β | β | β | β | β | β | β | β206.3% | 24.7% | 42.9% |
| Net margin | β | β | β | β | β | β | β | 21.6% | 30.7% | 52.6% |
| FCF margin | β | β | β | β | β | β | β | β198.4% | 41.0% | 48.6% |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β | β61.2% | β76.9% | β47.7% | 20.7% | 43.6% |
| Return on capital employed | β | β18.5% | β14.6% | β13.8% | β13.2% | β15.2% | β25.7% | β16.7% | 7.6% | 14.8% |
| Return on equity | β | β31.8% | β13.4% | β12.1% | β13.0% | β15.7% | β25.1% | 1.7% | 10.3% | 18.9% |
| Return on assets | β | β30.3% | β13.1% | β11.7% | β12.4% | β14.9% | β23.6% | 1.6% | 9.5% | 17.1% |
| Growth | ||||||||||
| Revenue growth | β | β | β | β | β | β | β | β | 473.0% | 33.9% |
| Net income growth | β | β | β | β | β | β | β | β | 715.6% | 129.7% |
| EPS growth | β | β | β | β | β | β | β | β | 669.2% | 128.0% |
| FCF growth | β | β | β | β | β | β | β | β | β | 58.5% |
| Share count change | β | 510.9% | 109.0% | 41.9% | 18.2% | 18.2% | 14.9% | 8.9% | 7.2% | 0.7% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β | β | β | β | β | β | β | β8.3x | β5.0x |
| Debt / equity | 4.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | β | β | β | β | β | β45.8x | β | β | β | β |
| Current ratio | 50.4x | 78.0x | 43.4x | 58.9x | 17.8x | 17.2x | 13.3x | 17.8x | 7.3x | 10.0x |
| Quick ratio | 50.4x | 78.0x | 43.4x | 58.9x | 17.8x | 17.2x | 13.3x | 17.6x | 7.0x | 9.6x |
| Capital allocation | ||||||||||
| Capex / revenue | β | β | β | β | β | β | β | 23.3% | 1.5% | 3.1% |
| Stock comp / revenue | β | β | β | β | β | β | β | 78.8% | 16.9% | 14.0% |
| Payouts / FCF | β | β | β | β | β | β | β | β | 0.0% | 0.0% |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | β | β | β | β | 2.0 | 4.0 | 5.0 | 5.0 |
| Altman Z'' | 1.3 | 86.4 | 46.1 | 39.6 | 20.4 | 22.0 | 15.9 | 23.1 | 12.9 | 16.6 |
| Accruals ratio | β | β15.4% | β1.7% | β0.2% | β2.3% | β4.6% | β6.7% | 14.5% | β3.7% | 0.3% |
Source: SEC EDGAR XBRL filings (CIK 0001711279). Data updated October 16, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
